Dengue is a mosquito-borne infection of growing international public health importance, found in both tropical and sub-tropical regions, predominantly in urban and semi-urban areas. Severe dengue, a potentially lethal complication, affects most Asian and Latin-American countries and has become a leading cause of hospitalization and death among children in the region.
With no specific drug candidate for dengue treatment in sight, TDR supported an analysis of the dengue drug research portfolio which is available on the web (see below) to help identify candidates, facilitate interactions and promote R&D.
TDR research is also identifying how to improve classification and surveillance and outbreaks. A revised disease classification lead by TDR and WHO’s department of neglected tropical diseases is being tested and adopted in countries.
- New series on helminth infections R&D agenda
- Dengue control support through eco-bio-social approach
- A call for closer ties to communities
- Pipeline grows for neglected diseases research and development (R&D)
- VL elimination by 2015 on track with new research
- Onchocerciasis can be eliminated with ivermectin
- VL rapid diagnostics may be inadequate in Brazil and East Africa